OKI-219 — Topline data
2026
We expect to report data from the monotherapy and fulvestrant combination arms of PIKTure-01 together with initial data from the triplet expansion arms (Parts C and E) in 2026.Source filing
OKUR biotech catalysts & pipeline
ONKURE THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
PI3K a inhibitors — Initial data
2026
We plan to announce additional information on our vascular malformations program in 2026.Source filing
OKI-219 — Topline data
Late 2026
The Company plans to report data from PIKture-01 by the end of 2026.Source filing
OKI ‑ 345 — IND submission
H1 2027
OnKure plans to submit an IND application to the FDA for OKI ‑ 345 in the first half of 2027.Source filing
OKI ‑ 355 — IND submission
H1 2027
OnKure plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for OKI ‑ 355 in the first half of 2027.Source filing
OKI-345 — IND submission
H1 2027
We plan to submit an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration for each of OKI-345 and OKI-355 in the first half of 2027.Source filing
OKI-355 — IND submission
H1 2027
We plan to submit an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration for each of OKI-345 and OKI-355 in the first half of 2027.Source filing